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ABSTRACT
We have been using the rat /3-tropomyosin ((3-TM) gene
as a model system to study the mechanism of
alternative splicing. The /3-TM gene spans 10 kb with
11 exons and encodes two distinct isoforms, namely
skeletal muscle /3-TM and f ibroblast TM-1. Exons 1 -5 ,
8, and 9 are common to all mRNAs expressed from this
gene. Exons 6 and 11 are used in fibroblasts, as well
as in smooth muscle cells, whereas exons 7 and 10 are
used exclusively in skeletal muscle cells. Our previous
studies localized the critical elements for regulated
alternative splicing to sequences within exon 7 and the
adjacent upstream intron. We also demonstrated that
these sequences function, in part, to regulate splice-
site selection in vivo by interacting with cellular factors
that block the use of the skeletal muscle exon in
nonmuscle cells (1). Here we have further characterized
the critical c/s-acting elements involved in alternative
splice site selection. Our data demonstrate that exon
7 and its flanking intron sequences are sufficient to
regulate the suppression of exon 7 in nonmuscle cells
when flanked by heterologous exons derived from
adenovirus. We have also shown by both in vivo and
in vitro assays that the blockage of exon 7 in
nonmuscle cells is primarily at its 3'-splice site. A model
is presented for regulated alternative splicing in both
skeletal muscle and nonmuscle cells.
INTRODUCTION
Alternative RNA splicing is a fundamental process in eukaryotes,
that contributes to tissue-specific and developmentally regulated
patterns of gene expression (2,3). The cellular factors and
mechanisms that are responsible for the selection of alternative
splice sites in complex transcription units are beginning to be
understood (for reviews see 2—4). The most progress has been
made in Drosophila systems such as in the genes of the sex
determination pathway, suppressor of white apricot and
Drosophila f-transposase. In these systems alternative splicing
is subject to regulation by factors that either inhibit or activate
the use of alternative 5' or 3' splice sites (3—5). In contrast,
in vertebrate systems, much less is known about the mechanisms
and cellular factors involved in regulated alternative splicing, but
a number of features in the pre-mRNA have been implicated in
alternative splice site selection. These include the relative
strengths of 5' and 3' splice sites (6-8), intron size (9), the
pyrimidine content of a 3' splice site (10,8), the location of branch
points (11-15), multiple alternative branch points (16,17,11,12),
branch point sequences (8,18,19,20), intron sequences between
a 3' splice site and upstream branch point (14,15,20), and exon
sequences (1,12,21 -23,,24-26,20,27,28,29,30).
We have been using the rat /3-TM gene as a model system to
investigate the mechanisms responsible for developmental and
tissue-specific alternative RNA splicing (1,12,14,31—33). This
gene spans 10 kb of DNA with 11 exons and encodes two distinct
isoforms, namely skeletal muscle /3-TM and fibroblast TM-1
(Figure 1). Exons 1 through 5, 8 and 9 are common to all
mRNAs expressed from this gene. Exons 6 and 11 are used in
fibroblasts, as well as smooth muscle, whereas exons 7 and 10
are used exclusively in skeletal muscle. Unlike most branch points
that have been mapped, in which a single adenosine residue
located 18-40 nucleotides from a 3' splice site is used during
lariat formation (34), in vitro splicing of exon 5 to exon 7 (skeletal
muscle-type splice) involved the use of multiple branchpoints
which are located an unusually long distance (144, 147 and 153
nucleotides) from the 3' splice site of exon 7 (32). We
subsequently investigated the functional role of the intron
sequences between the distant branchpoints and the 3 ' splice site
of the skeletal muscle exon 7. Our results demonstrated that two
distinct functional elements are present in this region (14). The
first element is comprised of a polypyrimidine tract located
89—143 nucleotides upstream of the 3' splice site, which specifies
the location of the branch points used, 144-153 nucleotides
:
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upstream of exon 7. The second element is comprised of intron
sequences located between the polypyrimidine tract and the 3'
splice site of exon 7. This region contains an important
determinant in alternative splice site selection because deletions
or mutations of these sequences results in the use of the skeletal
muscle-specific exon in nonmuscle cells (1,14). We found that
sequences contained within the 5' end of exon 7 are also involved
in blocking the use of exon 7 in nonmuscle cells (1). In addition,
mutations that inactivated the 5'- and 3'-splice sites of exon 6
did not result in the use of the skeletal muscle-specific exon 7
in nonmuscle cells, demonstrating that splice site selection in vivo
is not regulated by a simple cw-acting competition mechanism,
but rather by a mechanism that inhibits the use of exon 7 in certain
cellular environments (1).
In order to study in greater detail how sequences in and around
exon 7 prevent the use of this exon in nonmuscle cells, we have
further analyzed the m-elements involved in splice site selection.
These studies extend our previous observations and demonstrate
that the critical cw-elements for regulated alternative splicing are
confined to sequences within exon 7 and the adjacent upstream
intron. We also demonstrate that the blockage of exon 7 in
nonmuscle cells is primarily at its 3'-splice site.
MATERIALS AND METHODS
Plasmid construction and transfection
For in vivo studies designed to analyze the internal pair of
alternative exons of the rat /3-TM gene, plasmids pSV40-p2 and
pSV40-p2(7/8) were used (12). For in vitro splicing assay,
pSP64-p2(7/8) was used (12). The chimeric adenovirus-/3-
tropomyosin minigene was derived from a clone kindly provided
by Douglas Black (28), by replacing sequences from HindEI site
in intron 1 to Sail site in intron 2 of adenovirus major transcription
unit with /3-tropomyosin sequences, spanning 163 nucleotides
upstream of exon 7 to 25 nucleotides downstream of exon 7.
Mutations were introduced into these clones from previously
described mutants (1) by standard subcloning methods (35).
Transfections and RNA harvesting were performed as described
previously (1).
PCR assays
For analyzing the splice products from adenovirus chimeric gene
transcripts, the primers previously described by Black were used
(28). They are (1) CTCAAGGGGCTTCATGATGTCC,
complementary to the /3-globin trailer sequences in pEVRFl; (2)
TCCGATCCGGTCGATGCGGACTCG, complementary to the
third exon of the adenovirus major late transcription unit; (3)
CAGCGCCTTGTAGAAGCGCGTATG, homologous to the
leader sequence of pEVRFl. To visualize the PCR products by
autoradiography, primer 3 was 5'-end labeled with 3 2 P-YATP
(35). To make cDNA of the mRNA, 3 ng of total cellular RNA
were annealed to 3 ng primer 1 and reverse transcribed in a 30-jil
reaction according to the protocol of Smale and Baltimore (1989).
After reverse transcription, the sample was diluted to 60 /il, and
5 /tl of which was used for PCR.
For analyzing the splice products from /3-TM minigenes, four
primers were used. They are: (1) TTTTGGAGGCCTAGGC-
TTTT, homologous to the SV40 leader sequences; (2) TTTGCC-
ACAGATCTTTCAGC, complementary to exon 9 sequences of
/3-TM; (3) CACCTCGGCTCTCTC, complementary to exon 5
sequences of /3-TM; (4) GTCCGCTTGGGCTTCCAGAG,
complementary to exon 7 sequences. Primer 1 was 5' end labeled
with 32P7ATP. cDNAs were made with same method as above,
except that 200 pmol of random hexamers were used in the
reverse transcription.
The PCR reactions included 20 cycles of 94° for 1 min, 55°
for 1 min, and 72° for 1 min 45 sec, followed by 72° for 10
min. The PCR products were extracted with pheneol/chloroform,
ethanol precipitated, and analyzed on a 6% polyacrymide/8M
urea gel. The gel was dried and analyzed by autoradiography.
Synthesis of RNA and in vitro splicing reaction
The 32P-labeled pSP64-p2(7/8) were synthesized in vitro,
primed with CAP analog, as described (36). HeLa cell nuclear
extracts were prepared as described (37). In vitro splicing
reactions, as described previously (12), were carried out at 30°
for 120 min. 15 /il nuclear extract were used in a reaction volume
of 25 y\ that consisted of 1 mM MgCl2, 500 /*M ATP, 20 mM
creatine phosphate, 2.6% (wt/vol) poly vinyl alcohol, 60 mM
KC1, 0.12 mM EDTA, and 0.6 mM dithiothreitol (DTT).
RESULTS
Intron sequences upstream and downstream of exon 7 are
sufficient to regulate the suppression of exon 7 flanked by
heterologous exons
Our previous studies have identified cw-acting elements that
inhibit the use of exon 7 (skeletal muscle exon) in nonmuscle
cells (14,1). The elements are located in the intron immediately
of exon 7 and at the 5'-end of exon 7, since mutations (deletions
or base substitutions) at these regions result in the activation of
exon 7 splicing in nonmuscle cells. To determine if these elements
are sufficient to suppress exon 7 splicing in a nonmuscle cell
environment, we have made a chimeric minigene shown in
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Figure 1. Exon-intron organization of the rat 0-tropomyosin gene. Open boxes represent common exons, hatched and closed boxes represent tissue-specific exons
as indicated. Horizontal lines represent introns; they are not drawn to scale. The amino acids encoded by each exon are indicated. The CAP site and polyadenylation
sites are also indicated.
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Figure 2. The chimeric minigene was composed of adenovirus
major late transcription unit driven by cytomegalovinis (CMV)
promoter/enhancer, the tropomyosin exon 7 and its immediate
flanking region was inserted replacing die adenovirus exon 2.
The inserted TM gene segment contained sequences immediately
upstream of the branch point of exon 7 through 25 nucleotides
downstream of exon 7. We also prepared chimeric minigenes
with /3-TM segments containing three individual mutations. We
previously characterized these three mutations, termed int-3, int-5
and d3-5, in the context of/3-TM gene sequences and found that
they are capable of activating exon 7 splicing in nonmuscle cells
(1). The int-3 and int-5 mutants contain clustered point mutations
of GGATCC instead of wild-type sequence TGTCTC and
ACGCCC, respectively. The d3-5 mutant contains a 22
nucleotide deletion from int-3 to int-5 position. The wild type
and mutant heterologous minigenes were transfected into HeLa
cells. After 48 hours incubation, cytoplasmic RNA was isolated
and analyzed by reverse transcription-PCR analysis. As shown
in Figure 2, the splice product for die wild-type heterologous
minigene is adenovirus exon 1 spliced to adenovirus exon 3, and
the use of exon 7 of the TM gene is not detected. On the other
hand, mutants int-3 and int-5 can partially activate the use of exon
7 flanked by adenovirus exons, as shown by the splice product
/3-TM Exon 7
of adenovirus exon 1 to TM exon 7 to adenovirus exon 3
(Figure 2). Furthermore, mutant d3-5, which completely
activated exon 7 usage in the context of the natural TM gene
flanking exons (1), almost completely activated exon 7 splicing
in the heterologous genes. These results demonstrate that exon
7 and its immediate flanking intron regions are sufficient for the
regulation of exon 7 splicing in a nonmuscle cellular environment.
Intron sequences in the 5' half of intron 6 do not affect
alternative splice site selection
Recent work on the chicken /3-TM gene demonstrated that die
intron region 37 nucleotides downstream of the nonmuscle exon
6 was involved in the negative regulation of splicing of the skeletal
muscle-specific exon 7 in nonmuscle cells (38,39). To examine
if this cw-element is also present in rat /3-TM gene, we have
introduced into plasmid pS V40-p2 a series of deletion mutations
ranging from 17 nucleotides to 197 nucleotides downstream of
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Figure 2. Exon 7 and its flanking intron sequences are sufficient to regulate the
suppression of exon 7 when flanked by heterologous exons derived from
adenovirus. (Top) Schematic diagram of the chimeric minigene used in HeLa
cell transfection. The position of the branchpoint sequences (BPS) (black dot)
and adjacent polypyrimidine tract (black box) in intron 6 are also indicated. The
wild type and mutant chimeric minigenes (right) were transfected into HeLa cells
and the cytoplasmic RNA harvested 48 hours later. The RNAs were analyzed
by RT-PCR assay using a primer complementary to adenovirus exon 3 and a
primer homologous to adenovirus exon 1 that is 5' end labeled with 32P-7ATP.
Arrows (Top) represent the primers used in the PCR assay. The top bands in
the autoradiograph correspond to splice products of adenovirus exon 1 to exon
7 of TM gene to adenovirus exon 3. The bottom bands correspond to splice
products adenovirus exon 1 to adenovirus exon 3. Marker lane are markers using
pBR322 digested with Msp I.
Probe R T 5 | 6 | 8 | 9 |
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Figure 3. Deletions of sequences downstream of exon 6 does not affect alternative
splice site selection in nonmuscle cells. The position of the deletions were shown
previously (14). (Top) Schematic diagram of the tropomyosin minigene used in
HeLa cell transfection. The wild type and deletion mutants were transfected into
HeLa cells and the cytoplasmic RNA harvested 48 hours later. (Middle) Autographs
of RNase prelection analysis using cDNA probes derived from cDNA clones
encoding rat fibroblast TM-1 (left) and skeletal muscle /3-tropomyosin (right).
The band corresponding to the reference a-globin RNAs is labeled (ot-globin).
(Bottom) Schematic diagram of the structure of the RNA probe and protected
fragments (splice products).
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Figure 4. In vitro splicing of pre-mRNAs containing deletions of intron sequences
upstream of exon 7. The diagram at the right represents wild type and mutant
DNA templates derived from pSP64-p2(7/8) linearized with EcoSl. The positions
of branch point sequences (black dot) and polypyrimidine tract (black box) in
intron 6 are also indicated. In vitro splicing reactions were carried out for 2 hours,
and the 32P-labeled RNA products were seperated in a 4% denaturing
polyacrylamide gel. Schematic representation of the products and intermediates
are indicated to the left of autoradiographs and are (from top to bottom) pre-
mRNA, lariat/exon intermediate, free lariat, free lariat but 3' end is degraded
up until the lariat branchpoints by 3' exonucleolytic activity, splice product, and
free exon 5. Marker lane are markers using pBR322 digested with Mspl.
exon 6 (Figure 3). HeLa cells were transfected with minigenes
containing wild type or seven deletion mutants, and incubated
for 48 hrs. Cytoplasmic RNA was then isolated and analyzed
by RNase protection assay. The RNase protection analysis of
these RNA samples and RNA from mock-infected cells were
carried out with RNA probes derived from cDNA clones
encoding rat fibroblast TM-1 and skeletal muscle /3-TM
(Figure 3). Transient expression of wild-type minigene resulted
in spliced RNA that contained exons 5+6 + 8+9. A low level
of the skeletal muscle-type splice product, exons 5 + 7 + 8 + 9 ,
was detected in cells transfected with the wild-type construct,
which is similar to the observations with the chick /3-TM gene
in myoblast cells (20). Mutants d92/cd22, d81/cd22, dl5/cd22,
d85/cd22 and cd22, which deleted part or all of the polyprymidine
tract in intron 6, did not affect splicing of the upstream exon,
as shown by the normal levels of splicing of exons 5 + 6 + 8 + 9 .
They abolished the use of exon 7, which is consistent with our
Figure 5. RNA analysis of HeLa cells transfected with tropomyosin minigenes.
{Top) Schematic diagram of the tropomyosin minigenes used in the HeLa cell
transfections. The positions of branchpoint sequences (black dot) and adjacent
polypyrimidine tract (black box) are also indicated. The wild type and mutant
minigenes (right) were transfected into HeLa cells and the cytoplasmic RNA
harvested 48 hours later. The RNAs were analyzed by RT-PCR assay using primers
complementary to exon 7 and exon 5 sequences, and a primer homologous to
SV40 leader sequences that is 5' end labeled with 32P-7ATP. Arrows (Top)
represent primers used in the PCR assay. The top bands in the autoradiograph
correspond to splice products exon 5 to exon 7. The bottom bands correspond
to the reference.
in vitro and in vivo data that this polypyrimidine tract is important
for proper splicing of exon 5 to exon 7 (14). None of the
mutations that deleted intron sequences from 17 to 197 nucleotides
downstream of exon 6 led to significant activation of exon 7
usage, as shown by the lower levels of the spliced RNA product
containing exons 5 + 7 + 8 + 9 , relative to the level derived from
the wild-type construct. These mutants also do not seem to affect
the use of exon 6 (fibroblast-type splice) in HeLa cells. These
results indicate that in the rat /3-TM gene the intron sequences
between the 5' splice site of exon 6 and the branch sites upstream
of exon 7 are not involved in the negative regulation of exon
7 splicing in nonmuscle cells.
The blockage of exon 7 splicing in nonmuscle cells occurs at
its 3-splice site
As described above, we previously demonstrated that the cis-
elements responsible for the blockage of exon 7 splicing are
located in exon 7 and the adjacent upstream intron. However,
the mechanism of the blockage is not clear, although we have
shown that the blockage is mediated by cellular factors (1). To
determine whether the blockage of exon 7 splicing occurs at its
5'-splice site, 3'-splice site, or both, we have prepared wild-type
as well as three intron mutants of plasmid P2(7/8) that have exon
7 and exon 8 ligated together, and used them for both in vitro
and in vivo assays (Figures 4 and 5). In vitro splicing reactions
were carried out for 120 min. Following the reaction, the RNAs
were fractionated on a 4% polyacrylamide/urea gel (Figure 4).
As shown in Figure 4, wild-type P2(7/8) produced a relatively
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Figure 7. Model for alternative splicing of /3-tropomyosin pre-mRNA in nonmuscle
and skeletal muscle cells. For a discussion see text.
8 9 10 II 12 13 14 15
Figure 6. Mutants that have strong activation of exon 7 splicing also reduce the
level of exon skipping in vivo. The position of base substitution mutants and deletion
mutants were shown previously (1). (Top) Schematic diagram of the tropomyosin
minigene used in HeLa cell transfection. The wild type and mutants were
transfected into HeLa cells and the cytoplasmic RNA harvested 48 hours later.
The RNAs were analyzed by RT-PCR assay using primers complementary to
exon 9 and exon 5, and a primer homologous to SV40 leader sequences that is
5' end labeled with 32P-7ATP. Arrows (Top) represent primers used in the PCR
assay. The top bands in the autoradiograph correspond to splice products of exon
5 to 6 to 8 to 9 and/or exon 5 to 7 to 8 to 9. The middle bands correspond to
skipping products of exon 5 to 8 to 9. The bottom band was produced by a primer
antisense to exon 5 as a control to normalize initial starting amount of cellular
RNAs being used.
low level of spliced RNA of exons 5+7 + 8. By contrast, the
three mutants that have deleted the intron regulatory element
produced significantly higher amount of spliced products of exons
5+7 + 8 (Figure 4). For the in vivo assay, we have transfected
SV40P2(7/8) wild type and mutant plasmids into HeLa cells and
cytoplasmic RNAs were isolated 48 hrs after transfection and
analyzed by reverse transcription-PCR assay. In agreement with
the in vitro data, the wild-type construct produced the splice
product with exons 5+7 at a very low level, and the mutants
exhibited significantly higher amounts of exon 5 to exon 7 splice
product in the in vivo transient expression assay (Figure 5).
Although our previous data showed that splicing of exon 5 to
exon 7 required precursors in which exon 7 was first joined to
exon 8 (12), yet compared with the mutants that have deleted
the intron regulatory sequences the wild-type still spliced very
inefficiently in this construct. In addition, our previous results
have shown that precursors containing exon 7, intron 7 and exon
8 exhibit efficient splicing of exon 7 to exon 8 in vitro (31,14).
Collectively these results demonstrte that the blockage of exon
7 in nonmuscle cells is primarily at its 3'-splice site.
Mutants that have strong effect in activation of the exon 7
splicing also reduce exon skipping in vivo
By using reverse transcription-PCR method, we can detect proper
as well as aberrant splice products generated in transient
expression systems that could not be detected by the RNase
protection assay. We have examined a series of constructs
containing wild-type as well as mutants that have been previously
using the RNase protection assay (1). As shown in Figure 6, using
a 5' primer containing the SV40 leader sequence and a 3' primer
complementary to exon 9 for PCR amplification, we detected
a substantial amount of exon skipping product, i.e, splice product
containing exons 5+8+9, when cells were transfected with the
wild-type construct. However, mutants Exl, d3-5, d2-5 and dl-6
that almost fully activate skeletal muscle exon 7 splicing in Hela
cells (1), significantly reduced the amount of exon skipping.
DISCUSSION
The data presented in this paper demonstrates that the suppression
of exon 7 splicing is regulated by sequences around exon 7 when
put into a heterologous minigene (Figure 2). This is consistent
to our previous results showing that critical elements for regulated
alternative splicing of exon 7 are located at exon 7 and its
upstream intron sequences (1). Although the mechanism of exon
7 blockage in nonmuscle cells is unclear, we proposed according
to our previous studies, that cellular blocking factors are involved
(1). Here we have shown that the blockage of exon 7 splicing
is primarily at its 3'-splice site. Although it was previously shown
that splicing of exon 5 to exon 7 in vitro and in vivo can occur
in a nonmuscle cell system if exon 7 is first joined to exon 8
(12), our present results demonstrate that this splicing is relatively
inefficient with the wild type sequences. However, mutations in
the intron regulatory region upstream of exon 7 resulted in a
increased splicing efficiency both in vivo and in vitro (Figures
4 and 5). These results indicate that the suppression of exon 7
splicing by blocking factors in nonmuscle cells is primarily at
its 3'-splice site. Similar results have been reported for the human
a-tropomyosin gene (40).
The mechanism by which the 3'-splice site of exon 7 is blocked
in nonmuscle cells remains to determined. We have found that
the polypyrimidine tract binding protein (PTB) can interact with
the intron regulatory elements upstream of exon 7 (33). It is
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unclear at present how the binding of PTB to these sequences
contributes to splice site regulation. In addition, we cannot
exclude the possibility that other factors will bind to these
sequences and thereby block the use of this 3'-splice site. Work
is currently underway to study the interaction of factors that are
known to act on 3'-splice sites, e.g., U2 snRNP, U2AF, and
to determine if the interaction of such factors are regulated in
nonmuscle cells.
Using reverse transcription PCR analysis we found that
transient expression of the wild type tropomyosin minigene results
in both authentic splice product, i.e., exons 5+6+8+9 , as well
as the exon skipping product, exons 5 + 8+9 (Figure 6). Why
exon-skipping occurred in the cells is not clear but it could be
due to several possible mechanisms. One is that there may be
limiting factors that promote exon 6 splicing in HeLa cells. Thus
when cells were transfected with the minigene, the amount of
pre-mRNA transcribed from the minigene exceeded the amount
of the factors required for proper splicing. The nature of these
factors are currently not known, and could be general splicing
factors like SR proteins or other unknown proteins. For example,
recent studies have shown that SF2/ASF and hnRNP Al can
regulate exon inclusion or skipping in vitro (41). In vitro splicing
of /3-TM minigene that include sequences from exon 5 to 9,
resulted in exon skipping, such that the product was 5 + 8+9.
Upon addition of SF2/ASF, this inappropriate exon skipping
event was markedly prevented, thereby allowing inclusion of the
nonmuscle-type exon 6, which is the expected splicing pattern
in HeLa cells (41). It is possible that exon skipping observed
in the transient expression assay (Figure 6) is due to insufficient
amount of SF2/ASF in the cell relative to the amount of RNA
expressed from the minigene. In the future, it will be interesting
to co-transfect SF2/ASF cDNA with pSV40-p2 to see if the exon
skipping event will be prevented by increasing the amount of
SF2/ASF in the cell. Another possible mechanism for the exon
skipping event generated by transient expression of the minigene
is chromosome positioning. It has been shown that snRNPs and
splicing factor SC35 co-localized within the speckled nuclear
domains that may correspond to the sites of spliceosome assembly
and splicing itself (42,43). The position of the natural /3-TM gene
in the chromosome relative to the spatial localization of certain
splicing factors might be important for proper splicing.
Interestingly, mutations that activate the use of the skeletal
muscle exon 7 in nonmuscle cells suppressed exon-skipping
(Figure 6). Transient expression of the exon 7 mutant Exl, and
intron mutants d3-5, d2-5 and d 1-6 in HeLa cells resulted in
almost 100% splice product of exon 5 + 7 + 8 + 9 (Figure 6), and
very little or no skipping products were detected (Figure 6).
These mutations derepressed exon 7 splicing presumably by
interfering with the interaction of blocking factors. Therefore,
in the absence of blocking factors there could be sufficient general
splicing factors binding to this region and promoting exon 7
usage. The nature of these factors is unknown. They could be
the same factors required for proper exon 6 splicing or different
factors specifically required for exon 7 splicing. Another feature
of exon 7 is that it has a long polypyrimidine tract upstream of
its 3'-splice site (14). Studies of the rat a-TM gene have shown
that a long polypyrimidine tract adjacent to the branch point, as
well as a strong consensus branchpoint, determine a strong
3'-splice site, and presumably provide strong binding sites for
mww-acting factors that act early in the spliceosome formation
(8). It is possible that in the absence of blocking factors, the long
polypyrimidine tract upstream of exon 7 enables more trans-
acting factors to bind, resulting in efficient exon 7 splicing and
little or no skipping, whereas exon 6 does not have a strong
polypyrimidine tract, and less factors bind there and therefore
more skipping products will be generated.
Our previous studies indicated that the critical step in the use
of the nonmuscle exon 6 occurs during the joining of exon 6 to
the downstream common exon 8 (12). Although we previously
demonstrated that joining exon 7 to exon 8 resulted in splicing
of exon 7 in nonmuscle cells both in vitro and in vivo, it is clear
from the present studies that these precursors are spliced relatively
inefficiently. The data presented in this paper are consistent with
a model in which the critical step in the use of the skeletal muscle-
specific exon 7 is activation of it's 3'-splice site (Figure 7). In
the absence of the effects of blocking factors, exon 7 becomes
the default exon of choice because of its stronger 3'-splice site.
In addition, although this and previous studies from our laboratory
indicate that the use of the skeletal muscle exon in nonmuscle
cells is subject to negative regulation via blocking factors (1,33),
it remains to be determined how regulation is achieved in skeletal
muscle. Whether or not regulation in skeletal muscle is via
repression of blocking factors or expression of a splice site
activator remains to be determined. Our results do not rule out
the possibility that positive-acting factors will be required in
skeletal muscle cells to promote the use of exon 7. Work is
currently underway to study the factors that block the use of exon
7 in nonmuscle cells and to develop a cell-free assay system from
myogenic cells.
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